Answers are grounded in this paper and cite their sources.
Biomarkers have been used in the diagnosis of disease and other conditions for many decades.There are diverse ranges of analytical targets, including metabolites, nucleic acids and proteins were used as a biomarker.Clinical diagnoses already rely heavily on these for patient disease classifi cation, management, and informing treatment and care pathways.For that there is always a need of rapid and point of care test.However, until fairly recently, studies of biomarker effi cacy in a clinical setting were mainly limited to single or dual use, and the landscape was complex, confused, and often inconsistent.Few candidates emerged from this somewhat clouded picture: C-reactive protein, procalcitonin (PCT) for sepsis, ADA for mycobacterium tuberculosis and a Circulating miRNAs serve as molecular markers for diverse physiological and pathological conditions.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: